Liposome-mediated transfer of the bcl-2 gene results in neuroprotection after in vivo transient focal cerebral ischemia in an animal model
Open Access
- 1 March 2002
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 9 (6) , 415-419
- https://doi.org/10.1038/sj.gt.3301676
Abstract
Acute cerebral ischemia causes hypoxic neuronal cell death by necrosis and apoptosis. Expression of anti-apoptotic transgenes in ischemic brain may provide a useful therapeutic strategy for alleviation of postischemic damage. The present study investigates liposome-mediated transfer of the human bcl-2 protein in a rat model of focal transient ischemia due to middle cerebral artery (MCA) occlusion. Two different types of plasmid vectors were used for bcl-2 expression: one driven by the constitutive cytomegalovirus promoter (pCMV) and another based on the hypoxia-inducible human vascular endothelial growth factor promoter (pHRE). Cationic liposome/plasmid DNA complexes (lipoplexes) were injected directly into the cerebrospinal fluid (CSF) of rats immediately after MCA occlusion. The brains of treated and control animals were analyzed 48 h later. Infarct volumes and numbers of apoptotic cells were quantified. Occlusion of the MCA resulted in ipsilateral cerebral infarcts in all study animals. Transfer of the bcl-2 gene resulted in high level widespread protein expression in the case of the pCMV-bcl2 plasmid, while animals treated with the pHRE-bcl2 vector showed lower expression levels of bcl2 which were in addition limited to the ischemic area. Treatment with pCMV-bcl2, but not with pHRE-bcl2, was able to significantly reduce the infarct volume, which was 109 ± 8 mm3 for pCMV-bcl2, 152 ± 29 mm3 for pHRE-bcl2, and 155 ± 18 mm3 for control animals. Animals transfected with either vector showed a significant reduction in numbers of apoptotic cells in the infarct and penumbra area compared with controls. There were no short-term neurological side-effects of the CSF injection of lipoplexes or of bcl-2 expression. In conclusion, the hypoxia-inducible bcl-2 expression mediated by intrathecal lipoplexes may represent a novel, biologically safe and lesion-selective therapeutic approach for neuroprotection after acute cerebral ischemia.Keywords
This publication has 22 references indexed in Scilit:
- Gene therapy for preventing neuronal death using hepatocyte growth factor: in vivo gene transfer of HGF to subarachnoid space prevents delayed neuronal death in gerbil hippocampal CA1 neuronsGene Therapy, 2001
- Adeno-associated virus vector-mediated bcl-2 gene transfer into post-ischemic gerbil brain in vivo: prospects for gene therapy of ischemia-induced neuronal deathGene Therapy, 2000
- Temporal changes in sensitivity of rats to cerebral ischemic insultJournal of Neurosurgery, 2000
- Gene Expression along the Cerebral-Spinal Axis after Regional Gene DeliveryHuman Gene Therapy, 1999
- Liposome-mediated NGF gene transfection following neuronal injury: potential therapeutic applicationsGene Therapy, 1999
- BCL-2 Transduction, Using a Herpes Simplex Virus Amplicon, Protects Hippocampal Neurons from Transient Global IschemiaExperimental Neurology, 1999
- Herpes Simplex Viral Vectors Expressing Bcl-2 Are Neuroprotective When Delivered After a StrokeJournal of Cerebral Blood Flow & Metabolism, 1997
- Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosisGene Therapy, 1997
- Long-Term Survival in a Rodent Model of Disseminated Brain Tumors by Combined Intrathecal Delivery of Herpes Vectors and Ganciclovir TreatmentHuman Gene Therapy, 1996
- Expression of bcl-2 From a Defective Herpes Simplex Virus–1 Vector Limits Neuronal Death in Focal Cerebral IschemiaStroke, 1995